Insulin resistance and increased risk for malignant neoplasms: Confounding of the data on insulin glargine

Diabetologia

Volumn 53, Issue 1, 2010, Pages 206-208

  Nagel, J M ^a   Mansmann, U ^b   Wegscheider, K ^c   Rohmel J ^d  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d NONE   (Germany)

Author keywords

Data quality; Diabetes; Epidemiology; Glargine; Insulin analogue; Methodology; Neoplasm; Observational study

Indexed keywords

GLUCOSE; HUMAN INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO;

CANCER MORTALITY; CANCER RISK; DATA BASE; DIABETIC PATIENT; DRUG MEGADOSE; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HEALTH INSURANCE; HUMAN; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; LETTER; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL;

COHORT STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; NEOPLASMS; RISK FACTORS; SAFETY;

EID: 72449205431     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-009-1535-0     Document Type: Letter

References (8)

1. LG Hemkens U Grouven R Bender, et al. 2009 Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study Diabetologia 52 1732 1744 10.1007/s00125-009-1418-4 1:CAS:528: DC%2BD1MXpsFyrsL0%3D 19565214
2. P Kurtzhals L Schaffer A Sorensen, et al. 2000 Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use Diabetes 49 999 1005 10.2337/diabetes.49.6.999 1:CAS:528: DC%2BD3cXjvFylu7w%3D 10866053
3. Scherbaum WA, Kiess W (eds) (2004) Epidemiologie und Verlauf des Diabetes mellitus in Deutschland. Available from www.deutsche-diabetes-gesellschaft.de/ leitlinien/EBL-Epidemiologie-Update-2004.pdf, accessed 4 September 2009
4. W Rathmann G Giani 2004 Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 2568 2569 10.2337/diacare.27.10.2568 15451946 author reply 2569 (Pubitemid 39281428)
5. SJ Pocock L Smeeth 2009 Insulin glargine and malignancy: an unwarranted alarm Lancet 374 511 513 10.1016/S0140-6736(09)61307-6 19616841
6. Jewell NP (2004) Statistics for epidemiology. Chapman & Hall/CRC, Boca Raton
7. K Zendehdel O Nyren CG Ostenson HO Adami A Ekbom W Ye 2003 Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden J Natl Cancer Inst 95 1797 1800 14652242 (Pubitemid 38008903)
8. D LeRoith R Novosyadlyy EJ Gallagher D Lann A Vijayakumar S Yakar 2008 Obesity and type 2 diabetes are associated with an increased risk of developing cancer and a worse prognosis; epidemiological and mechanistic evidence Exp Clin Endocrinol Diabetes 116 Suppl 1 S4 S6 10.1055/s-2008-1081488 1:CAS:528:DC%2BD1cXhtlCgsr7O 18777452